NASDAQ:SANA

Sana Biotechnology (SANA) Stock Forecast, Price & News

$3.77

-0.10 (-2.58%)

(As of 10:39 AM ET)

Compare

Today's Range: $3.74
▼
$3.86
50-Day Range: $3.77
▼
$5.98
52-Week Range: $2.99
▼
$8.01

Volume: 159,069 shs
Average Volume: 1.13 million shs
Market Capitalization: $742.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.40

Sana Biotechnology MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 142.9% Upside
$9.40 Price Target
Short Interest: Bearish
22.94% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.70
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.57) to ($1.51) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

561st out of 969 stocks

Biological Products, Except Diagnostic Industry

83rd out of 162 stocks

3.3

Analyst's Opinion

Consensus Rating
Sana Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.40, Sana Biotechnology has a forecasted upside of 142.9% from its current price of $3.87.
Amount of Analyst Coverage
Sana Biotechnology has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
22.94% of the float of Sana Biotechnology has been sold short.
Short Interest Ratio / Days to Cover
Sana Biotechnology has a short interest ratio ("days to cover") of 25, which indicates bearish sentiment.
Change versus previous month
Short interest in Sana Biotechnology has recently decreased by 3.67%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Sana Biotechnology does not currently pay a dividend.
Dividend Growth
Sana Biotechnology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SANA.

3.2

News and Social Media Coverage

News Sentiment
Sana Biotechnology has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Sana Biotechnology this week, compared to 2 articles on an average week.
Search Interest
8 people have searched for SANA on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sana Biotechnology insiders have not sold or bought any company stock.
Percentage Held by Insiders
34.90% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
68.37% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sana Biotechnology are expected to grow in the coming year, from ($1.57) to ($1.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sana Biotechnology is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sana Biotechnology is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sana Biotechnology has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sana Biotechnology (NASDAQ:SANA) Stock

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255, a B cell maturation antigen directed allogeneic CAR T for multiple myeloma; SC45, the PSC-derived pancreatic islet cells for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, Huntington's disease, and other astrocytic diseases. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is based in Seattle, Washington.

SANA Price History

30 days | 90 days | 365 days | Advanced Chart

SANA Stock News Headlines

September 28, 2023 | americanbankingnews.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $9.50 Average PT from Brokerages

September 26, 2023 | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Receives New Coverage from Analysts at JMP Securities

October 2, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.

September 25, 2023 | msn.com

JMP Securities Initiates Coverage of Sana Biotechnology (SANA) with Market Outperform Recommendation

September 25, 2023 | americanbankingnews.com

Analyzing Sana Biotechnology (NASDAQ:SANA) and VectivBio (NASDAQ:VECT)

September 25, 2023 | markets.businessinsider.com

Promising Prospects and Diversified Portfolio Bolster Sana Biotechnology’s Investment Appeal: A Buy Rating Analysis

September 24, 2023 | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Shares Down 3.3%

September 14, 2023 | seekingalpha.com

Sana Biotechnology falls after pipeline updates

October 2, 2023 | Wall Street Fundamentals (Ad)

How is This "Hidden Gem" Thriving in a Turbulent Market?

While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.

September 11, 2023 | finance.yahoo.com

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

September 8, 2023 | msn.com

This Cathie Wood Stock Is Down 40% in 2023. Here's Why She's Still Buying It.

September 5, 2023 | markets.businessinsider.com

Sana Biotechnology (SANA) Initiated with a Buy at Citi

August 30, 2023 | finance.yahoo.com

Sana Biotechnology to Present at September 2023 Investor Conferences

August 14, 2023 | msn.com

TD Cowen Initiates Coverage of Sana Biotechnology (SANA) with Market Perform Recommendation

August 14, 2023 | finance.yahoo.com

Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines

August 3, 2023 | msn.com

Sana Biotechnology Non-GAAP EPS of -$0.45 misses by $0.02

August 3, 2023 | finance.yahoo.com

Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates

August 3, 2023 | msn.com

Business briefs: Biotech breaks ground on new Bothell facility

August 1, 2023 | seekingalpha.com

Sana Biotechnology: Uncertainties Shadowing The Potential

July 31, 2023 | bizjournals.com

Sana breaks ground on manufacturing facility in Bothell

July 24, 2023 | finance.yahoo.com

Specific Biologics Strengthens Scientific Advisory Board with Appointment of Tirtha Chakraborty, Ph.D. and Mike Nicholson, Ph.D.

July 18, 2023 | finance.yahoo.com

UPDATE 1-Pfizer, Flagship Pioneering to invest $100 mln in drug discovery

July 18, 2023 | msn.com

Pfizer, Flagship Pioneering to invest $100 million in drug discovery

July 18, 2023 | reuters.com

Pfizer, Flagship Pioneering to invest $100 mln for drug discovery

July 13, 2023 | finance.yahoo.com

Flagship Pioneering Announces Appointment of Rupert Vessey as Chief Scientist

July 11, 2023 | finance.yahoo.com

APIE Therapeutics Appoints Ashwin Datt Chief Executive Officer

July 9, 2023 | seekingalpha.com

Sana Biotechnology: Hypoimmune Platform Might Stealth Cells

See More Headlines

Receive SANA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

SANA Company Calendar

Last Earnings: 8/03/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SANA
CUSIP: N/A
CIK: 1770121
Web: sana.com
Phone: 206-701-7914
Fax: N/A
Employees: 424
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.40
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +142.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-269,480,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -73.07%
Return on Assets: -42.55%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.02
Quick Ratio: 3.02

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.62 per share
Price / Book: 1.48

Miscellaneous

Outstanding Shares: 196,940,000
Free Float: 128,209,000
Market Cap: $762.16 million
Optionable: Not Optionable
Beta: 0.70

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Steven D. Harr M.D. (Age 53)
Pres, CEO & Director
Comp: $1.04M

Dr. Richard C. Mulligan Ph.D. (Age 68)
Exec. Vice Chairman & Head of SanaX

Mr. Bernard J. Cassidy J.D. (Age 68)
Exec. VP, Gen. Counsel & Corp. Sec.
Comp: $491.39k

Mr. Nathan Hardy M.B.A. (Age 47)
Exec. VP & CFO

Brittany Mccleery
Accounting Mang.

Dr. Edward Rebar Ph.D. (Age 55)
Sr. VP & CTO

Ms. Robin Andrulevich (Age 57)
Exec. VP & Chief People Officer

Mr. Paul Brunetta M.D.
Sr. VP and Head of Clinical & Translational Science

Mr. Christian Hordo M.B.A. (Age 40)
Exec. VP & Chief Bus. Officer

Dr. Sonja Schrepfer M.D. (Age 48)
Ph.D., Sr. VP & Head of Hypoimmune Platform

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SANA Stock - Frequently Asked Questions

Should I buy or sell Sana Biotechnology stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SANA shares.
View SANA analyst ratings or view top-rated stocks.
What is Sana Biotechnology's stock price forecast for 2023?: 6 brokers have issued 12 month target prices for Sana Biotechnology's stock. Their SANA share price forecasts range from $6.00 to $13.00. On average, they anticipate the company's share price to reach $9.40 in the next twelve months. This suggests a possible upside of 142.9% from the stock's current price.
View analysts price targets for SANA or view top-rated stocks among Wall Street analysts.
How have SANA shares performed in 2023?: Sana Biotechnology's stock was trading at $3.95 at the start of the year. Since then, SANA shares have decreased by 2.0% and is now trading at $3.87.
View the best growth stocks for 2023 here.
When is Sana Biotechnology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our SANA earnings forecast.
How were Sana Biotechnology's earnings last quarter?: Sana Biotechnology, Inc. (NASDAQ:SANA) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.03.
What ETFs hold Sana Biotechnology's stock?: ETFs with the largest weight of Sana Biotechnology (NASDAQ:SANA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA).IQ U.S. Small Cap ETF (CSML).

When did Sana Biotechnology IPO?: (SANA) raised $322 million in an IPO on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO.
What is Sana Biotechnology's stock symbol?: Sana Biotechnology trades on the NASDAQ under the ticker symbol "SANA."
How do I buy shares of Sana Biotechnology?: Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Sana Biotechnology's stock price today?: One share of SANA stock can currently be purchased for approximately $3.87.
How much money does Sana Biotechnology make?: Sana Biotechnology (NASDAQ:SANA) has a market capitalization of $762.16 million. The company earns $-269,480,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.
How many employees does Sana Biotechnology have?: The company employs 424 workers across the globe.
How can I contact Sana Biotechnology?: Sana Biotechnology's mailing address is 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102. The official website for the company is sana.com. The company can be reached via phone at 206-701-7914 or via email at investor.relations@sana.com.

This page (NASDAQ:SANA) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial